Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MaaT033 in Axial Spondyloarthritis
NCT05654753Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2024
- Primary completion
- Sep 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in axial spondyloarthritis (axSpA) comparing MaaT033 with Placebo (2 arms). Primary endpoints: Increase in gut Metagenome Species Pangenome (MSP) richness at Day 42 and Proportion of patients satisfying ASAS 20 improvement criteria at Day 42. Started Mar 2024; status: recruiting.
02
Drugs
MaaT-033
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT05654753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05654753.